Gsa Capital Partners LLP Cytom X Therapeutics, Inc. Transaction History

Gsa Capital Partners LLP

$1.11 Billion
Q1 2025

A detailed history of Gsa Capital Partners LLP transactions in Cytom X Therapeutics, Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 762,930 shares of CTMX stock, worth $717,154. This represents 0.04% of its overall portfolio holdings.

Number of Shares

762,930

Previous 38,885 1862.02%

Holding current value

$717,154

Previous $40,000 1112.5%

% of portfolio

0.04%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 08, 2025	BUY	$0.58 - $1.14 $419,946 - $825,411	724,045 Added 1862.02%	762,930 $485,000
Q4 2024 Feb 07, 2025	BUY	$0.86 - $1.29 $33,441 - $50,161	38,885 New	38,885 $40,000
Q2 2024 Aug 15, 2024	BUY	$1.21 - $5.13 $97,436 - $413,098	80,526 Added 54.2%	229,093 $279,000
Q1 2024 May 03, 2024	BUY	$1.41 - $2.74 $62,611 - $121,669	44,405 Added 42.63%	148,567 $323,000
Q4 2023 Feb 16, 2024	BUY	$1.07 - $1.55 $111,453 - $161,451	104,162 New	104,162 $161,000
Q2 2023 Aug 14, 2023	BUY	$1.41 - $1.92 $485,278 - $660,804	344,169 New	344,169 $591,000
Q4 2021 Feb 14, 2022	SELL	$3.87 - $7.39 $964,195 - $1.84 Million	-249,146 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$4.32 - $6.43 $1.08 Million - $1.6 Million	249,146 New	249,146 $1.27 Million
Q2 2021 Aug 05, 2021	SELL	$6.33 - $9.91 $120,858 - $189,211	-19,093 Closed	0 $0
Q1 2021 May 10, 2021	SELL	$6.6 - $9.0 $84,222 - $114,849	-12,761 Reduced 40.06%	19,093 $148,000
Q4 2020 Feb 03, 2021	BUY	$6.47 - $7.9 $23,311 - $28,463	3,603 Added 12.75%	31,854 $209,000
Q3 2020 Nov 06, 2020	SELL	$6.55 - $8.83 $81,770 - $110,233	-12,484 Reduced 30.65%	28,251 $188,000
Q2 2020 Aug 11, 2020	SELL	$7.4 - $14.64 $153,039 - $302,769	-20,681 Reduced 33.67%	40,735 $339,000
Q1 2020 May 12, 2020	SELL	$3.61 - $8.6 $198,911 - $473,860	-55,100 Reduced 47.29%	61,416 $471,000
Q4 2019 Feb 12, 2020	BUY	$5.17 - $8.91 $199,143 - $343,204	38,519 Added 49.39%	116,516 $968,000
Q3 2019 Nov 12, 2019	BUY	$7.38 - $12.25 $90,788 - $150,699	12,302 Added 18.73%	77,997 $576,000
Q2 2019 Aug 06, 2019	BUY	$9.35 - $11.41 $280,845 - $342,722	30,037 Added 84.24%	65,695 $737,000
Q1 2019 May 15, 2019	BUY	$9.5 - $19.16 $9,101 - $18,355	958 Added 2.76%	35,658 $383,000
Q4 2018 Feb 12, 2019	SELL	$12.69 - $18.61 $2,538 - $3,722	-200 Reduced 0.57%	34,700 $524,000
Q3 2018 Nov 13, 2018	SELL	$18.04 - $26.41 $272,404 - $398,791	-15,100 Reduced 30.2%	34,900 $646,000
Q2 2018 Aug 09, 2018	BUY	$21.38 - $29.68 $880,150 - $1.22 Million	41,167 Added 466.06%	50,000 $1.14 Million
Q1 2018 May 11, 2018	BUY	$21.76 - $34.22 $192,206 - $302,265	8,833 New	8,833 $251,000

Others Institutions Holding CTMX

# of Institutions

Shares Held

46.7M

Call Options Held

3.7K

Put Options Held

4.7K

View Full List

About CytomX Therapeutics, Inc.

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $62M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

More about CTMX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Gsa Capital Partners LLP with notifications on news.

Account

Gsa Capital Partners LLP Cytom X Therapeutics, Inc. Transaction History